Alembic Pharmaceuticals: 7 Stock Signals Investors Are Watching Right Now

Alembic Pharmaceuticals CMP Rs 854.35. 52W range Rs 635.80-998.00. Mcap Rs 16,518 crore. PE 23.96 vs sector 38.56.

Alembic Pharmaceuticals stock signals are unusually layered right now, with the company trading at Rs 854.35, 14.4% below its 52-week high of Rs 998.00 and 34.4% above its 52-week low of Rs 635.80. Alembic Pharmaceuticals is a well tracked name in the pharmaceutical formulations and active pharmaceutical ingredients space, and no single headline captures where the stock stands today.

This article does not make a buy, hold or sell call on Alembic Pharmaceuticals. It lays out seven signals investors commonly watch, each sourced from the company’s latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.

Click Here – Get Free Investment Predictions

Alembic Pharmaceuticals Stock at a Glance

Before going through each of the seven Alembic Pharmaceuticals stock signals in detail, the snapshot below sets the starting point on price, valuation and balance sheet strength.

1. Earnings Trend at Alembic Pharmaceuticals

Alembic Pharmaceuticals posted trailing-twelve-month revenue of Rs 7,847 crore versus Rs 7,399 crore a year earlier, while net profit moved to Rs 690 crore from Rs 671 crore, a change of 2.8% on the year. The most recent quarter added Rs 2,164.70 crore in revenue, a change of 26.1% year on year, against Rs 172.36 crore in net profit versus Rs 153.63 crore a year earlier.

net profit was up close to 12% year on year in the June 2026 quarter as revenue grew over 26%, extending trailing-twelve-month growth of close to 3%. This is the first of the seven Alembic Pharmaceuticals stock signals worth tracking closely into the next results.

2. FII Holding in Alembic Pharmaceuticals

A full quarterly FII holding series was not available from the data source used here for Alembic Pharmaceuticals. Where that is the case, the most reliable next step is to check the company’s latest exchange filing directly, since a single-quarter snapshot can be misleading without the trend around it.

This is worth revisiting once the next quarterly shareholding disclosure is filed.

3. Promoter Holding in Alembic Pharmaceuticals

Promoter holding in Alembic Pharmaceuticals promoter and institutional shareholding figures were not available from the data source used here; investors can check the company’s latest exchange filing directly.

This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.

4. Debt Position at Alembic Pharmaceuticals

Alembic Pharmaceuticals’s debt to equity ratio stands at 0.25, one of the balance sheet metrics worth tracking alongside the earnings trend above. A lower or stable ratio generally gives more room to fund growth without leaning further on external borrowing, while a rising one is worth watching for its effect on finance costs.

This debt signal should be read alongside the valuation and corporate development signals below rather than in isolation, since capital raising plans can shift the picture from one quarter to the next.

5. Valuation of Alembic Pharmaceuticals Shares

At the current price, Alembic Pharmaceuticals trades at a price to earnings ratio of 23.96, a discount of close to 37.9% versus the sector average of 38.56. The price to book ratio stands at 2.91.

Whether that discount looks justified depends on the earnings trend from Signal 1 continuing, and it is one of the clearer places where the seven signals can pull in different directions at the same time.

6. Technical Trend on the Alembic Pharmaceuticals Chart

The stock last traded around Rs 854.35, above its short-term average of about Rs 844.40, pointing to near-term strength. The 14-day RSI reads close to 36, in neutral territory. The MACD line sits below its signal line, a bearish momentum bias.

Over the past year the stock is currently 14.4% below its 52-week high of Rs 998.00 and 34.4% above its 52-week low of Rs 635.80. A sustained move back above its recent average would be an early technical sign of stabilisation.

7. Corporate Developments at Alembic Pharmaceuticals

Alembic Pharmaceuticals received final USFDA approval for an Abbreviated New Drug Application in late June 2026, and net profit rose close to 29% year on year in the March 2026 quarter, as the integrated pharmaceutical company expands its generics and API business.

Check the Univest Screener for live fundamentals

What These Alembic Pharmaceuticals stock signals Mean Together

None of these seven signals on its own settles the debate on Alembic Pharmaceuticals. Reading them as a set, rather than picking out any single one, is the more balanced way to approach the stock right now. The earnings trend, shareholding pattern, balance sheet position, valuation, technical setup and corporate developments each add one piece of the picture, and they do not all point the same way at the same time.

Investors weighing Alembic Pharmaceuticals would do well to watch the next quarterly results for a read on where margins and profit are heading, alongside the next shareholding pattern update for any shift in institutional positioning. Reading these Alembic Pharmaceuticals stock signals together, rather than in isolation, remains the more balanced approach. As with any single stock, price movements can be volatile and past trends do not guarantee future performance.

For context, investors following Alembic Pharmaceuticals often look at how the stock has moved through previous earnings cycles, how peer companies in the same space have reacted to similar corporate developments, and whether broader market conditions such as interest rate moves, sector-wide policy shifts or commodity price swings have played a larger role than company-specific news. None of these broader factors replace the seven signals above, but they help explain why a stock can move sharply even when no single company-specific trigger is visible in the data. Reading a stock’s price action purely in isolation, without this wider lens, can lead to drawing conclusions that do not hold up once the next quarter’s numbers or the next shareholding disclosure comes in. Investors are generally better served treating each of these seven factors as one input among several, updated on a rolling basis as new disclosures arrive, rather than as a one-time checklist filled in once and then set aside for the rest of the year without a further look.

Also Read: HDFC Bank: 7 Stock Signals Investors Are Watching Right Now

Conclusion

Alembic Pharmaceuticals currently sits at the intersection of several moving parts, from earnings and shareholding to valuation and chart trend, and that is exactly what the seven signals above are meant to surface. This article does not recommend buying, holding or selling Alembic Pharmaceuticals shares, and readers should form their own view based on their own research and risk appetite.

Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals live price and more such signal based stock research.

FAQs on Alembic Pharmaceuticals Stock Signals

Why is Alembic Pharmaceuticals share price where it is right now?

Ans. Alembic Pharmaceuticals shares are trading 14.4% below their 52-week high of Rs 998.00 and 34.4% above their 52-week low of Rs 635.80, shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.

What is Alembic Pharmaceuticals’s current FII holding?

Ans. A full quarterly FII holding series was not available for this article; check the company’s latest exchange filing directly.

Is Alembic Pharmaceuticals’s debt position a concern right now?

Ans. The debt to equity ratio stands at 0.25.

What is the promoter holding in Alembic Pharmaceuticals?

Ans. promoter and institutional shareholding figures were not available from the data source used here; investors can check the company’s latest exchange filing directly.

Is Alembic Pharmaceuticals expensive compared to its sector?

Ans. Alembic Pharmaceuticals trades at a price to earnings ratio of 23.96 against a sector average of 38.56.

What recent corporate developments are relevant to Alembic Pharmaceuticals?

Ans. Alembic Pharmaceuticals received final USFDA approval for an Abbreviated New Drug Application in late June 2026, and net profit rose close to 29% year on year in the March 2026 quarter, as the integrated pharmaceutical company expands its generics and API business.

What do the technical charts suggest about Alembic Pharmaceuticals right now?

Ans. The stock is trading above its short-term average of about Rs 844.40, pointing to near-term strength, with its MACD line below its signal line, a bearish momentum bias.

Should investors buy Alembic Pharmaceuticals shares at current levels?

Ans. This article does not offer a buy, hold or sell recommendation. It lays out seven Alembic Pharmaceuticals stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.